ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z
  • Abstract Number: 2536
    Vagus Nerve Stimulation in Patients with Rheumatoid Arthritis: 24 Month Safety and Efficacy
  • Abstract Number: 2400
    Validating and Developing a Selected Questionnaire to Predict Early Diagnosis of Juvenile Idiopathic Arthritis in German Population
  • Abstract Number: 1673
    Validation and Evaluation of the Spanish Version of the Systemic LUPUS Activity Questionnaire in an Argentine Population
  • Abstract Number: 647
    Validation of a New Electronic Spinal Mobility Index for Patients with Axial Spondyloarthritis Based on Inertial Motion Unit (IMU) Sensors
  • Abstract Number: 1378
    Validation of a Spanish Version of the Functional Index for Hand Osteoarthritis (FIHOA)
  • Abstract Number: 653
    Validation of Assessments in Spondyloarthritis International Society MRI Lesion Definitions in Axial Spondyloarthritis: Data from the Echography in Spondyloarthritis Cohort
  • Abstract Number: 1540
    Validation of Hepatic Fibrosis Markers in People with Rheumatoid Arthritis on Methotrexate
  • Abstract Number: 2928
    Validation of New Systemic Lupus Erythematosus Classification Criteria
  • Abstract Number: 1712
    Validation of Proposed EULAR/Acr SLE Classification Criteria Versus SLICC SLE Classification Criteria
  • Abstract Number: 2929
    Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
  • Abstract Number: 458
    Validation of the 2012 Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria Compared to the 1997 Acr Criteria and 2017 Candidate Weighted Criteria for Lupus in Pediatric Patients
  • Abstract Number: 1338
    Validation of the Diagnostic Accuracy of Myositis-Related Antibodies in a Large Patient-Cohort
  • Abstract Number: 2728
    Validation of the Draft Classification Criteria of Granulomatosis with Polyangiitis (GPA) Amongst Indian Patients with ANCA Associated Vasculitis
  • Abstract Number: 200
    Validation of the Ers-RA Risk Score in a Dutch Population
  • Abstract Number: 2471
    Validation of the Functional Index for Hand Osteoarthritis (FIHOA) in Patients with Rheumatoid Arthritis
  • Abstract Number: 671
    Validation of the Rexspa (Reductive X-Ray Score for Psoriatic Arthritis) in an Argentinean Cohort of Patients with Psoriatic Arthritis
  • Abstract Number: 302
    Validity and Responsiveness of Inflammation and Joint Damage Scores Based on the Omeract Rheumatoid Arthritis MRI Scoring System
  • Abstract Number: 1635
    Validity of Patient-Reported Outcomes Measurement Information System Measures in Ankylosing Spondylitis Patients
  • Abstract Number: 1837
    Validity of the Cognitive Index of the Symptom Severity Scale (SSS-Cog) in Assessing Cognitive Impairment in Fibromyalgia Patients
  • Abstract Number: 1484
    Value of Anti-RA33 Isotypes in an European Rheumatoid Arthritis Patient Cohort
  • Abstract Number: 2736
    Value of Histology for Diagnosis and Classification in ANCA Associated Vasculitis
  • Abstract Number: 2724
    Variable Response to Induction Therapy and Significant Burden of Treatment Adverse Events over the First 12 Months in Incident ANCA-Associated Vasculitis (AAV) Patients – a Study of Routine Clinical Practice in the EU
  • Abstract Number: 1683
    Variation in HEp-2 Antinuclear Antibody (ANA) Titer Is Strongly Associated with the ANA Kit Manufacturer
  • Abstract Number: 2872
    Variation in Predictors of Patient and Physician Defined Flares in Rheumatoid Arthritis
  • Abstract Number: 1060
    Variation in the Synovial Fluid Metabolome According to Disease Activity in Rheumatoid Arthritis
  • Abstract Number: 279
    Variations and Disparities in Healthcare Teams Among Individuals with Lupus
  • Abstract Number: 2008
    Vascular Adhesion Protein-1 (VAP-1) As Predictor of Radiographic Severity in Symptomatic Knee Osteoarthritis
  • Abstract Number: 2075
    Vascular Endothelial and Inflammatory Differences in Psoriasis and Psoriatic Arthritis Patients
  • Abstract Number: 2993
    Vascular Involvement in Behcet’s Syndrome May be Associated with Subclinical Atherosclerosis
  • Abstract Number: 2364
    Vasculitis Patient Journey: A Scoping Review of Patient Experiences with Vasculitis
  • Abstract Number: 2721
    Venous Thromboembolism in ANCA Associated Vasculitis. a Population-Based Cohort Study from Southern Sweden
  • Abstract Number: 1794
    Venous Vessel Wall Thickness in Lower Extremity Is Increased in Male Behcet’s Disease Patients
  • Abstract Number: 2337
    Vertebral Compression Fractures and Antibodies to Citrullinated Vimentin in Established Rheumatoid Arthritis
  • Abstract Number: 1731
    Vertebral Fracture Prevalence and Measurement of the Scanographic Bone Attenuation Coefficient on CT-Scan in 70 Patients with Systemic Scleroderma
  • Abstract Number: L07
    VIB4920, a Novel, Engineered CD40L Antagonist Decreased Disease Activity and Improved Biomarkers of Immune Activation in Patients with Active Rheumatoid Arthritis in a Phase 1b, Multiple-Ascending Dose Proof-of-Concept Study
  • Abstract Number: 504
    Views of Primary Care Physicians and Rheumatologists Regarding Screening and Management of Hyperlipidemia Among Patients with Rheumatoid Arthritis
  • Abstract Number: 222
    Viral Exposures As a Risk Factor for Rheumatoid Arthritis: Summarizing the Evidence
  • Abstract Number: 2454
    Virus Reactivation Rate in Rheumatoid Arthritis Using Tofacitinib
  • Abstract Number: 818
    Visual Involvement in Giant Cell Arteritis: A Prospective Multi Center Study
  • Abstract Number: 1557
    Visualization of Dorsal Root Ganglionitis with Three-Tesla Magnetic Resonance Neurography in Sensory Ataxic Neuropathy Associated with Sjögren’s Syndrome
  • Abstract Number: 2330
    Vitamin D and Bisphosphonate Therapy in SLE Patients Who Receive Glucocorticoids: Are We Offering the Best Care?
Jump to:  View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology